In the increasingly complex environment of MS there is a need for better cross-talk and communication between the different stakeholders who each address MS according to their own perspective.
Objective & Methods:
The first and second Pan-European MS Multi-stakeholder Colloquia were specifically set-up for this.
Results:
In May 2014 and May 2015, the different stakeholders in MS (patients, healthcare professionals, regulators, payers and pharmaceutical industry professionals) met to present and discuss each other’s perspective, formulate 10 integrated Calls to Actions (first Colloquium) and discuss guidance propositions/recommendations developed by working groups for the Calls to Action (second Colloquium).
Conclusion:
The perspectives of the different stakeholders and the 10 integrated Calls to Action are summarised in this supplement.
KremenchutzkyMCottrellDRiceG. The natural history of multiple sclerosis: A geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: A re-evaluation. Brain1999; 122: 1941–1949.
4.
PreiningerovaJLTurCZiemssenT.What are important treatment goals for multiple sclerosis patients and how to capture this by means of different attributes in clinical practice?Abstract and poster presented at the First Pan-European multi-stakeholder colloquium, Exploring opportunities and challenges for improving Multiple Sclerosis management, 23–24 May 2014, Brussels, Mirrors of Medicine, 2014, 18 (abs. 13). ISSN: 2034–8393.
5.
NaciHFleurenceRBirtJ. Economic burden of multiple sclerosis: A systematic review of the literature. Pharmacoeconomics2010; 28: 363–379.
6.
OrmeMKerriganJTyasD. The effect of disease, functional status and relapses on the utility of people with multiple sclerosis in the UK. Value Health2007; 10: 54–60.
7.
KobeltGBergJLindgrenP. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry2006; 77: 918–926.
The first Pan-European multiple sclerosis multi-stakeholder colloquium: Exploring opportunities and challenges for improving multiple sclerosis management. Agenda, http://2014.ms-colloquium.org/programme (2014, accessed 3 December 2015).
VermerschPSmetsLGoldR. Conclusions: Calls to action for improving the life of MS patients and their families. Mult Scler2016; S2: 71–77.
13.
The second Pan-European multiple sclerosis multi-stakeholder colloquium: Accelerating adoption of innovation for better care. Agenda, http://ms-colloquium.org/programme (2015, accessed 3 December 2015).
14.
VermerschPFallerACzarnota-SzałkowskaD. The patient’s perspective: How to create awareness for improving access to care and treatment of MS patients?Mult Scler2016; S2: 9–17.
15.
VermerschPBergerTGoldR. The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?Mult Scler2016; S2: 18–33.
16.
CrommelinDJABroichKHollowayC. The regulator’s perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?Mult Scler2016; S2: 47–59.
17.
FeysPGiovannoniGDijsselbloemN. The importance of a multi-disciplinary perspective and patient activation programmes in MS management. Mult Scler2016; S2: 34–46.
18.
GoldRToumiMMeesenB. The payer’s perspective: What is the burden of MS and how should the patient’s perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment?Mult Scler2016; S2: 60–70.
